Clarity Pharmaceuticals Ltd (CLRPF)

Market Cap	1.07B
Revenue (ttm)	6.67M
Net Income (ttm)	-30.14M
Shares Out	n/a
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	5,163
Open	2.845
Previous Close	2.750
Day's Range	2.845 - 2.845
52-Week Range	0.842 - 6.398
Beta	1.63
RSI	73.94
Earnings Date	Aug 22, 2025

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 50
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLRPF

Financial Performance

In 2024, Clarity Pharmaceuticals's revenue was 11.51 million, an increase of 17.41% compared to the previous year's 9.80 million. Losses were -42.32 million, 72.0% more than in 2023.

Financial numbers in AUD